Clinical Trial News and Research

RSS

VX-770 drug candidate improves lung function in people with cystic fibrosis

In a study published in this week's New England Journal of Medicine, treatment with a new drug candidate known as VX-770 resulted in improvements in lung function and markers of disease in a Phase 2 clinical trial of 39 people with cystic fibrosis (CF). There were no discontinuations due to adverse events in the study, and the frequency of adverse events was similar across the study groups.

18 Nov 2010

Titan Pharmaceuticals presents data on Probuphine Phase 3 clinical program for opioid addiction at Neuroscience Meeting

Titan Pharmaceuticals, Inc. today announced that data from its Phase 3 clinical development program for Probuphine were presented at the Society for Neuroscience Annual Meeting, being held Nov. 13-17 in San Diego.

18 Nov 2010

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

Sangamo BioSciences, Inc. announced today the presentation of Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509, a zinc finger protein transcriptional activator (ZFP-TF) of the vascular endothelial growth factor (VEGF)-A gene as a treatment for ALS.

17 Nov 2010

Vical enters agreement with GenomIdea to develop DNA vaccine for pandemic influenza

Vical Incorporated today announced that the company has entered into an evaluation and supply agreement with GenomIdea Inc., a subsidiary of AnGes MG, Inc., for the development of a DNA vaccine for livestock against pandemic influenza.

17 Nov 2010

Combination of two devices increases long-term survival in cardiac arrest patients

A combination of two devices could save the lives of several thousand cardiac arrest patients each year if implemented nationwide, suggests results of a clinical trial presented at today's American Heart Association Resuscitation Science Symposium.

17 Nov 2010

Cardio3 BioSciences announces positive results from C-Cure Phase II clinical trial for heart failure

The Belgian biotechnology company, Cardio3 BioSciences a leader in discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases today announces positive six-month results, including significant functional and clinical benefit, from the Phase II clinical trial of its development programme C-Cure(R), designed as a novel stem cell therapy for heart failure based on breakthrough technology.

17 Nov 2010

Fat-derived stem cells can boost heart function following acute attack

Fat cells liposuctioned from a patient's belly can safely boost heart function after a heart attack, according to a first-of-its-kind study presented at the American Heart Association's Scientific Sessions 2010.

17 Nov 2010

Targeted therapies could treat a broad range of cancers: Research

Targeted cancer therapies such as trastuzumab (Herceptin), gefitinib (Iressa) and erlotinib (Tarceva) could be used to treat a wider range of cancers than previously thought, according to new research presented today (Wednesday) at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin.

17 Nov 2010

Infinity announces enrollment in IPI-926 Phase 1b/2 clinical trial for pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced that enrollment is ongoing locally for a Phase 1b/2 clinical trial of IPI-926, Infinity's oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway, in combination with Gemzar (gemcitabine) in patients with previously untreated, metastatic pancreatic cancer.

17 Nov 2010

NIH awards $10 million to advance technology for painless influenza vaccine delivery patch

The National Institutes of Health (NIH) has awarded $10 million to the Georgia Institute of Technology, Emory University and PATH, a Seattle-based nonprofit organization, to advance a technology for the painless, self-administration of flu vaccine using patches containing tiny microneedles that dissolve into the skin.

17 Nov 2010

USPTO issues patent to Neogenix’s 16C3 monoclonal antibody for colorectal, pancreatic cancer

Neogenix Oncology, Inc. announced today that the U.S. Patent and Trademark Office (USPTO) has issued patent number 7,829,678 B2, with claims relating to 16C3 antibody, the company's monoclonal antibody for colorectal and pancreatic cancer.

17 Nov 2010

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Alkermes, Inc. today announced the presentation of promising preclinical results for its proprietary opioid modulator, ALKS 33, showing the drug candidate's potential in multiple disease indications.

17 Nov 2010

TRITON–TIMI 38 substudy shows prasugrel reduces overall mortality rate in ACS patients

New results from an observational substudy from TRITON–TIMI 38 presented today at the American Heart Association (AHA) Scientific Sessions annual meeting showed that patients treated with Efient/Effient (prasugrel) prior to coronary artery bypass graft surgery (CABG) had a reduced overall mortality rate compared to patients treated with Plavix (clopidogrel)

17 Nov 2010

MRL announces acquisition of world's largest cryo-preserved human cancer tissue bank

Molecular Response (MRL), a privately held molecular diagnostic services company and a leader in the identification of target populations for high value therapeutics, announced today the acquisition of the world's largest cryo-preserved human cancer tissue bank—more than 144,000 specimens procured over 20 years. The company acquired the tumor bank, along with properly de-identified clinical information and validated test procedures, as part of a major acquisition of key assets formerly owned by Oncotech.

17 Nov 2010

UMass, PolyMedix receive Phase 2 STTR contract to conduct test on antimicrobial compounds

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, and the University of Massachusetts, Amherst (UMass), have received a Phase 2 Small Business Technology Transfer (STTR) contract in the amount of $750,000.

17 Nov 2010

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.

17 Nov 2010

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

Progenics Pharmaceuticals, Inc. today announced the initiation of a phase 2 clinical trial of subcutaneous methylnaltrexone in Japan by its collaborator, Ono Pharmaceutical Co., Ltd. The drug, designated ONO-3849 in Japan, is being evaluated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness such as cancer.

17 Nov 2010

Tengion permits second patient enrollment in Neo-Urinary Conduit for bladder cancer

Tengion, Inc., a leader in regenerative medicine, announced today that the scheduled one-month, post-operative clinical assessment of the first implanted bladder cancer patient in its ongoing clinical trial has been completed as expected and has permitted the second patient to be enrolled without delay.

16 Nov 2010

Stem cells for stroke: Clinical trial commences

Researchers have started the world’s first clinical trial of stem cells to treat stroke victims in Glasgow. The trial is undertaken by ReNeuron, a Guildford-based biotech company and started this weekend with an elderly man receiving an injection of 2 million stem cells into his brain. It received final approval to go ahead this year.

16 Nov 2010

Patrys announces capital raising of $3.2 million and share purchase plan

Patrys Limited (ASX: PAB; Company), a biotechnology company focused on the development of revolutionary new treatments for cancer, is pleased to announce a successful capital raising of approximately $3.2 million, which was conducted via a private placement.

16 Nov 2010

Clinical Trial News and Research

VX-770 drug candidate improves lung function in people with cystic fibrosis

Titan Pharmaceuticals presents data on Probuphine Phase 3 clinical program for opioid addiction at Neuroscience Meeting

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

Vical enters agreement with GenomIdea to develop DNA vaccine for pandemic influenza

Combination of two devices increases long-term survival in cardiac arrest patients

Cardio3 BioSciences announces positive results from C-Cure Phase II clinical trial for heart failure

Fat-derived stem cells can boost heart function following acute attack

Targeted therapies could treat a broad range of cancers: Research

Infinity announces enrollment in IPI-926 Phase 1b/2 clinical trial for pancreatic cancer

NIH awards $10 million to advance technology for painless influenza vaccine delivery patch

USPTO issues patent to Neogenix’s 16C3 monoclonal antibody for colorectal, pancreatic cancer

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

TRITON–TIMI 38 substudy shows prasugrel reduces overall mortality rate in ACS patients

MRL announces acquisition of world's largest cryo-preserved human cancer tissue bank

UMass, PolyMedix receive Phase 2 STTR contract to conduct test on antimicrobial compounds

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

Tengion permits second patient enrollment in Neo-Urinary Conduit for bladder cancer

Stem cells for stroke: Clinical trial commences

Patrys announces capital raising of $3.2 million and share purchase plan

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer